Posted by Michael Wonder on 27 Apr 2023
Even drugs winning fast-track nods frustrate before reimbursement wall
27 April 2023 - Several targeted agents for lung cancer approved through fast-track review due to their innovativeness and urgency of diseases have become useless faced with the wall called the “insurance benefits.”
That’s because seven targeted therapies targeting rare genetic mutations to treat non-small cell lung cancer (NSCLC) that have won approval over the past one-and-a-half years through the fast-track procedure remain on the “non-reimbursement” list.
